Biostate AI and the Accelerated Cure Project (ACP) have announced a strategic partnership to develop advanced AI models for multiple sclerosis (MS) treatment.
Utilising transcriptomic data from ACP’s biorepository, the collaboration aims to predict disease progression and treatment response, enhancing personalised care for MS patients.
The partnership marks Biostate’s entry into neuroimmunology and extends its portfolio of disease-specific AI models.
Biostate AI will sequence the entire ACP Repository and develop a series of AI models addressing a range of clinical and research questions.
By employing its proprietary barcode-integrated reverse transcription (BIRT) technology, Biostate AI will create high-resolution RNA expression profiles.
The profiles will be used to train transformer-based AI models that customise treatment strategies for MS patients.
Biostate AI co-founder and CEO David Zhang said: “Current MS management relies heavily on trial and error due to limited predictive tools.
“By combining high-throughput RNA sequencing with AI, we aim to equip clinicians with precise, data-driven guidance, ensuring patients receive appropriate therapy promptly.”
ACP chief scientific officer Stephanie Buxhoeveden said: “At ACP, we’ve dedicated years to building a resource designed to advance breakthroughs in MS research.
“By partnering with Biostate AI, we’re turning data into actionable insights that could revolutionize patient care.”
The ACP Repository contains thousands of blood samples from MS patients and controls, including longitudinal samples with comprehensive clinical and demographic data.
Its dataset enables the development of AI systems that identify molecular patterns linked to disease onset, relapse, remission, and treatment responses.
The models will improve the prediction of disease progression and identify patients most likely to benefit from therapies across the MS disease spectrum.
The partnership supports ACP’s mission to advance cures through collaboration, data sharing, and innovative science, allowing Biostate AI to expand its AI capabilities.
Accelerated Cure Project CEO Sara Loud said: “Biostate’s RNA sequencing and AI technologies offer a unique opportunity to transform our understanding of MS progression and treatment response.
“We are thrilled to collaborate with Biostate AI to unlock the full potential of our biorepository and accelerate innovations leading to better outcomes for people with MS.”
Biostate AI co-founder and CTO Ashwin Gopinath said: “Our goal is creating adaptable disease models tailored to individual patient biology, surpassing existing diagnostics.
“MS’s complexity and variability make it an ideal candidate for our approach, and we’re eager to collaborate with ACP to develop clinically actionable tools.”
